Kane Biotech Inc. announces that BioStem Technologies Inc. (BioStem ... including exclusive US distribution rights for Kane’s revyve antimicrobial wound gel. BioStem made the announcement on November ...

WINNIPEG, Manitoba, Nov. 27, 2024 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX- V ... rights for Kane’s revyveTM Antimicrobial Wound Gel. BioStem made the announcement on November 20, 2024.

(the “Company” or “Kane Biotech”) announces today that it has received Health Canada approval of its revyve™ Antimicrobial Wound Gel as a Class 2 Medical Device. This approval allows the ...

The company indicated that the acquisition of revyveTM Antimicrobial Wound Gel reflects BioStem's continued ... spectrum and around the world. Kane Biotech Inc. is a biotechnology company engaged ...

(“Kane Biotech” or“Kane”) announces that it is donating 2,000 ounces of revyveTM Antimicrobial Wound Gel to the Ukraine medical relief effort. The product will be used to assist in the ...

(“Kane Biotech” or “Kane”) announces that it is donating 2,000 ounces of revyve™ Antimicrobial Wound Gel to the Ukraine medical relief effort. The product ...